Compare JAZZ & TFII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | TFII |
|---|---|---|
| Founded | 2003 | 1957 |
| Country | Ireland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 9.1B |
| IPO Year | 2007 | 2012 |
| Metric | JAZZ | TFII |
|---|---|---|
| Price | $181.95 | $104.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $216.92 | $126.42 |
| AVG Volume (30 Days) | ★ 937.7K | 358.0K |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.86% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,618,693,000.00 | N/A |
| Revenue This Year | $6.17 | $1.11 |
| Revenue Next Year | $7.66 | $5.23 |
| P/E Ratio | ★ N/A | $31.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $95.49 | $72.02 |
| 52 Week High | $198.00 | $127.44 |
| Indicator | JAZZ | TFII |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 42.18 |
| Support Level | $176.67 | $104.63 |
| Resistance Level | $182.99 | $111.99 |
| Average True Range (ATR) | 4.96 | 3.62 |
| MACD | -0.94 | -1.08 |
| Stochastic Oscillator | 39.13 | 30.35 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
TFI International Inc is involved in the provision of transportation and logistics services across the United States, Canada, and Mexico. The company's reportable segments are; Less-Than-Truckload, which derives maximum revenue, Truckload, and Logistics. The Less-Than-Truckload segment engages in pickup, consolidation, transport, and delivery of smaller loads; the Truckload segment deals with full loads carried directly from the customer to the destination using a closed van or specialized equipment to meet customer's specific needs; and the Logistics segment provides asset-light logistics services, including brokerage, freight forwarding, and transportation management, as well as small package parcel delivery. Geographically, the company generates maximum revenue from the United States.